Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Identification of Hepatic-like Erythropoietin with Enhanced Activity As a New Cause of Hereditary and Acquired Erythrocytosis

Laurent Martin, Darko Maric, Salam Idriss, Marine Delamare, Amandine Le Roy, Nada Maaziz, Amandine Caillaud, Karim Si-Tayeb, Florence Robriquet, Marion Lenglet, Lucie Erceau, Christine Bellanné-Chantelot, Isabelle Plo, Bernard Aral, Céline Garrec, Fabrice Airaud, Clara Gianfermi, Vincent Antunes, Anna Keppner, Sarah Mathilda Vincent, Alexis Desfontaine, Nina Modé, Fabien Laporte, Anne Gaignerie, Caroline Chariau, Isabelle Leray, Coline Rogue, Laurent David, Richard Redon, Stephane Bezieau, Lamisse Mansour, Frederic Galacteros, Thibault Maillet, Marlène Pasquet, Pierre Cougoul, Anne-Marie Nloga, Claude Gardin, Corinne Guitton, Viviane Dubruille, Vannina Giacobbi-Milet, Thierry Leblanc, Zuhre Kaya, Denis Semama, Chloe James, Serge Carillo, Marlène Ochmann, Anders Waage, Erwan Mortier, Mike Maillasson, Agnès Quéméner, Holger Cario, Radek C. Skoda, Yaël Zermati, David Hoogewijs, Alexandre Marchand, Francois Girodon, Betty Gardie

Blood (2024) 144 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2024-213000

Published: 2024

Journal Articles

How I approach the treatment of thrombotic complications in patients with myeloproliferative neoplasms

Alexandre Guy, Pierre-Emmanuel Morange, Chloé James

Blood blood.2024025627.

https://doi.org/10.1182/blood.2024025627

Published: 2024

Journal Articles

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Blood (2024) 144 (Supplement 1): 6635.

https://doi.org/10.1182/blood-2024-199028

Published: 2024

Journal Articles

Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)

Blood (2024) 144 (Supplement 1): 3133.

https://doi.org/10.1182/blood-2024-194702

Published: 2024

Journal Articles

Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera

Yan Beauverd, Jean-Christophe Ianotto, Kyaw Htin Thaw, Marta Sobas, Parvis Sadjadian, Natalia Curto-Garcia, Lee-Yung Shih, Timothy Devos, Dorota Krochmalczyk, Serena Galli, Maria Bieniaszewska, Ilona Seferynska, Mary Frances McMullin, Anna Armatys, Adrianna Spalek, Joanna Waclaw, Mihnea Tudor Zdrenghea, Laurence Legros, Francois Girodon, Krzysztof Lewandowski, Anna Angona Figueras, Jan Samuelsson, Aitor Abuin Blanco, Pascale Cony-Makhoul, Angela Collins, Chloe James, Rajko Kusec, Marie Lauermannova, Maria Soledad Noya, Malgorzata Skowronek, Lukasz Szukalski, Anna Szmigielska-Kaplon, Marielle Wondergem, Iryna Dudchenko, Joanna Gora-Tybor, Kamel Laribi, Anna Kulikowska De Nalecz, Jean-Loup Demory, Katell Le Du, Sonja Zweegman, Carlos Besses Raebel, Radek C. Skoda, Stephane Giraudier, Martin Griesshammer, Jean-Jacques Kiladjian, Claire N Harrison

Blood (2023) 142 (Supplement 1): 748.

https://doi.org/10.1182/blood-2023-185108

Published: 2023

Journal Articles

Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Blood (2022) 140 (Supplement 1): 6847–6849.

https://doi.org/10.1182/blood-2022-156632

Published: 2022

Journal Articles

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Blood (2022) 140 (Supplement 1): 9668–9669.

https://doi.org/10.1182/blood-2022-159928

Published: 2022

Journal Articles

Description of a knock-in mouse model of JAK2 V617F MPN emerging from a minority of mutated hematopoietic stem cells

Olivier Mansier, Badr Kilani, Amélie V. Guitart, Alexandre Guy, Virginie Gourdou-Latyszenok, Caroline Marty, Marie Parrens, Isabelle Plo, William Vainchenker, Chloé James

Blood (2019) 134 (26): 2383–2387.

https://doi.org/10.1182/blood.2019001163

Published: 2019

Includes: Supplemental data

Journal Articles

Consequences of the Presence of the JAK2V617F Mutation in Endothelial Cells: Towards a Better Understanding of the Increased Angiogenesis in Myeloproliferative Neoplasms

Badr Kilani, Juliana Vieira Dias, PhD, Virginie Gourdou-Latyszenok, Eric Lippert, PhD, Raj Sewduth, Cécile Duplaa, PhD, Jean-Luc Villeval, PhD, Thierry Couffinhal, MD PhD, Chloe James, MD PhD

Blood (2014) 124 (21): 102.

https://doi.org/10.1182/blood.V124.21.102.102

Published: 2014

Journal Articles

Intrinsic Impairment of Platelet Production in Persistent/Chronic ITP

Etienne Riviere, Jean-François Viallard, MD, PhD, Juliana Vieira Dias, PhD, Anne Cecile Pons, Thierry Couffinhal, MD, PhD, Jean-Luc Pellegrin, MD, PhD, Chloe James, MD, PhD

Blood (2012) 120 (21): 624.

https://doi.org/10.1182/blood.V120.21.624.624

Published: 2012

Journal Articles

Mcl-1 and Bcl-x L coordinately regulate megakaryocyte survival

Marlyse A. Debrincat, Emma C. Josefsson, Chloé James, Katya J. Henley, Sarah Ellis, Marion Lebois, Kelly L. Betterman, Rachael M. Lane, Kelly L. Rogers, Michael J. White, Andrew W. Roberts, Natasha L. Harvey, Donald Metcalf, Benjamin T. Kile

Blood (2012) 119 (24): 5850–5858.

https://doi.org/10.1182/blood-2011-12-398834

Published: 2012

Journal Articles

Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function

Michael J. White, Simone M. Schoenwaelder, Emma C. Josefsson, Kate E. Jarman, Katya J. Henley, Chloé James, Marlyse A. Debrincat, Shaun P. Jackson, David C. S. Huang, Benjamin T. Kile

Blood (2012) 119 (18): 4283–4290.

https://doi.org/10.1182/blood-2011-11-394858

Published: 2012

Includes: Supplemental data

Journal Articles

Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia

Dominique Bluteau, Laure Gilles, Morgane Hilpert, Iléana Antony-Debré, Chloe James, Najet Debili, Valerie Camara-Clayette, Orianne Wagner-Ballon, Veronique Cordette-Lagarde, Thomas Robert, Hugues Ripoche, Patrick Gonin, Sabina Swierczek, Josef Prchal, William Vainchenker, Remi Favier, Hana Raslova

Blood (2011) 118 (24): 6310–6320.

https://doi.org/10.1182/blood-2010-12-325555

Published: 2011

Includes: Supplemental data

Journal Articles

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor–induced thrombocytopenia

Mark J. Bishton, Simon J. Harrison, Benjamin P. Martin, Nicole McLaughlin, Chloé James, Emma C. Josefsson, Katya J. Henley, Benjamin T. Kile, H. Miles Prince, Ricky W. Johnstone

Blood (2011) 117 (13): 3658–3668.

https://doi.org/10.1182/blood-2010-11-318055

Published: 2011

Includes: Supplemental data

Journal Articles

Analysis of the Ten-Eleven Translocation 2 ( TET2 ) gene in familial myeloproliferative neoplasms

Cécile Saint-Martin, Gwendoline Leroy, François Delhommeau, Gérard Panelatti, Sabrina Dupont, Chloé James, Isabelle Plo, Dominique Bordessoule, Christine Chomienne, André Delannoy, Alain Devidas, Martine Gardembas-Pain, Françoise Isnard, Yves Plumelle, Olivier Bernard, William Vainchenker, Albert Najman, Christine Bellanné-Chantelot, the French Group of Familial Myeloproliferative Disorders

Blood (2009) 114 (8): 1628–1632.

https://doi.org/10.1182/blood-2009-01-197525

Published: 2009

Includes: Supplemental data

Journal Articles

TET2 Is a Novel Tumor Suppressor Gene Inactivated in Myeloproliferative Neoplasms: Identification of a Pre-JAK2 V617F Event

Francois Delhommeau, Sabrina Dupont, Chloe James, MD, PhD, Aline Masse, Jean Pierre le Couedic, Veronique Della Valle, Antonio Alberdi, Philippe Dessen, Michaela Fontenay, Nicole Casadevall, MD, Jean Soulier, MD, PhD, Olivier Bernard, William Vainchenker

Blood (2008) 112 (11): lba-3.

https://doi.org/10.1182/blood.V112.11.lba-3.lba-3

Published: 2008

Journal Articles

The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity

Chloe James, Frederic Mazurier, Sabrina Dupont, Ronan Chaligne, Isabelle Lamrissi-Garcia, Micheline Tulliez, Eric Lippert, François-Xavier Mahon, Jean-Max Pasquet, Gabriel Etienne, François Delhommeau, Stephane Giraudier, William Vainchenker, Hubert de Verneuil

Blood (2008) 112 (6): 2429–2438.

https://doi.org/10.1182/blood-2008-02-137877

Published: 2008

Journal Articles

The Hematopoietic Stem Cell Compartment Is Different in Polycythemia Vera and Idiopathic Myelofibrosis.

Chloe James, MD, Frederic Mazurier, PhD, Ronan Chaligne, Sabrina Dupont, Francois Delhommeau, MD, PhD, Stephane Giraudier, MD, PhD, William Vainchenker, MD, PhD, Hubert De Verneuil, MD, PhD

Blood (2007) 110 (11): 259.

https://doi.org/10.1182/blood.V110.11.259.259

Published: 2007

Journal Articles

Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis

Ronan Chaligné, Chloé James, Carole Tonetti, Rodolphe Besancenot, Jean Pierre Le Couédic, Fanny Fava, Fréderic Mazurier, Isabelle Godin, Karim Maloum, Frédéric Larbret, Yann Lécluse, William Vainchenker, Stéphane Giraudier

Blood (2007) 110 (10): 3735–3743.

https://doi.org/10.1182/blood-2007-05-089003

Published: 2007

Journal Articles

The JAK2 617V > F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera

Sabrina Dupont, Aline Massé, Chloé James, Irène Teyssandier, Yann Lécluse, Frédéric Larbret, Valérie Ugo, Patrick Saulnier, Serge Koscielny, Jean Pierre Le Couédic, Nicole Casadevall, William Vainchenker, François Delhommeau

Blood (2007) 110 (3): 1013–1021.

https://doi.org/10.1182/blood-2006-10-054940

Published: 2007

Includes: Supplemental data

NARROW

Identification of Hepatic-like Erythropoietin with Enhanced Activity As a New Cause of Hereditary and Acquired Erythrocytosis

How I approach the treatment of thrombotic complications in patients with myeloproliferative neoplasms

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)

Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera

Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Description of a knock-in mouse model of JAK2 V617F MPN emerging from a minority of mutated hematopoietic stem cells

Consequences of the Presence of the JAK2V617F Mutation in Endothelial Cells: Towards a Better Understanding of the Increased Angiogenesis in Myeloproliferative Neoplasms

Intrinsic Impairment of Platelet Production in Persistent/Chronic ITP

Mcl-1 and Bcl-x L coordinately regulate megakaryocyte survival

Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function

Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor–induced thrombocytopenia

Analysis of the Ten-Eleven Translocation 2 ( TET2 ) gene in familial myeloproliferative neoplasms

TET2 Is a Novel Tumor Suppressor Gene Inactivated in Myeloproliferative Neoplasms: Identification of a Pre-JAK2 V617F Event

The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity

The Hematopoietic Stem Cell Compartment Is Different in Polycythemia Vera and Idiopathic Myelofibrosis.

Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis

The JAK2 617V > F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only